{
  "docId": "019de075-b7fd-707e-9848-cbfca2408f7c",
  "docSlug": "18b92232553b1610a38c1cd353f6efa7",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 28,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-b7fd-707e-9848-cbfca2408f7c/9",
  "deckHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c",
  "deckJsonHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c.json",
  "deckAnchorHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.88,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "diagram",
      "text": null,
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2569102-2df5-481d-aaa8-9f30e2303b8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.88,
        "x": 0.06,
        "y": 0.58
      },
      "kind": "list",
      "text": "Exceeded the primary endpoint threshold; All patients completing induction achieved CSF sterility; No breakthrough Infections; Survival at Day 30; MAT2203 was safe and well-tolerated over 6 weeks of treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14035419-5f72-47de-860d-a968584d4a32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.88,
        "x": 0.06,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "EFA for MAT2203 was 0.42 (95% CI 0.29 to 0.55) (primary endpoint threshold was 0.20); 97% for patients receiving MAT2203; 76% for patients receiving SOC; Over 10 weeks, patients showed no breakthrough infections post-MAT2203 treatment; 98% for patients receiving MAT2203; 88% for patients receiving IV Ampho (SOC); Repeat dosing showed no renal toxicity or electrolyte abnormalities; No discontinuations due to AEs nor MAT2203-related SAEs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "753b56e9-21fe-4973-87db-50750194957f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.25,
        "y": 0.19
      },
      "kind": "title",
      "text": "EnACT Clinical Data VALIDATES the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c058256f-5ee3-4893-9d95-9e3b79fbd14c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "EnACT : Cohort 2 Results (Validation of Efficacy and Safety)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8ea2028-eb97-4c8a-9063-f0a79d2ba59e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "0b3107a3-5f4f-4933-ab2a-0acdb105947d",
      "evidence": "The slide contains a title/action-title: 'EnACT Clinical Data VALIDATES the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity'",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "e1f32fa9-af9e-4bcf-b034-ec30706bff09",
      "evidence": "Sequential flow of clinical outcomes",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "837310e4-efa8-45cc-a3b9-2b7fbe0dc9e9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases traction for MAT2203, including market size and clinical results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5ea2f8a3-5d0e-48dd-a24c-65a56e44ddce",
      "evidence": "The deck presents the limitations of current antifungal treatments and the potential of MAT2203",
      "position": 0,
      "objective": "Highlight the need for new antifungal treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}